PTSD treatment market seen reaching $26.1 billion by 2031

Allied Market Research says the global post-traumatic stress disorder treatment market will grow from $16.0 billion in 2021 to $26.1 billion by 2031, driven by more clinical trials, R&D and government support. North America held the largest share in 2021, while drugs and pediatric treatment are projected to grow fastest.

Why it matters: - The PTSD treatment market is expanding as demand rises for both medication and psychotherapy. - Growth in treatment access could affect hospitals, mental health centers and outpatient clinics worldwide. - The forecast points to rising spending on mental health care, especially in North America and Asia-Pacific.

What happened: - Allied Market Research released a report on the global post-traumatic stress disorder treatment market covering 2021 to 2031. - The market was valued at $16.0 billion in 2021 and is projected to reach $26.1 billion by 2031. - The forecast implies a 4.9% compound annual growth rate from 2022 to 2031. - The report breaks the market down by treatment type, age group, end user and region. - The report includes a sample copy.

The details: - Clinical trials and research and development for new therapies and drugs are among the main growth drivers. - Government initiatives for PTSD treatment and management, along with higher healthcare spending in developing countries, are expected to support demand. - During the pandemic, psychotherapies declined for many patients, while drug and medication use increased. - The report says that trend continued until the pandemic ended. - By treatment type, psychotherapy held more than two-thirds of the market in 2021. - The drugs segment is projected to grow at a 6.5% CAGR through 2031. - By age group, adults accounted for nearly half of the market in 2021. - The pediatric segment is expected to post the fastest growth at 5.9% CAGR through 2031. - By end user, the market covers hospitals, outpatient clinics, mental health centers and other providers. - The report profiles Acadia Healthcare, Behavioral Health Network, CareTech Holdings, GlaxoSmithKline, Pfizer, Viatris, Strategic Behavioral Health, Ascension Seton, North Range Behavioral Health, Pyramid Healthcare and Eli Lilly. - The report also cites customization options for COVID-19-related requirements.

Between the lines: - North America held about two-fifths of global market share in 2021 and is expected to stay dominant. - That position reflects a heavier PTSD burden, active research and development, and a dense base of established market players. - Asia-Pacific is projected to grow the fastest, at 6.2% CAGR, which suggests rising diagnosis and treatment demand in the region. - The market mix still leans toward psychotherapy, but faster drug growth may signal broader adoption of pharmaceutical treatment options.

What's next: - The report expects broader market gains as clinical pipelines expand and governments keep funding PTSD care. - Adult treatment will likely remain the largest segment, while pediatric care could gain share as abuse-related cases rise. - Regional competition may intensify as Asia-Pacific growth outpaces mature markets. - More information is available in Allied Market Research's report overview.